Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Biweekly gemcitabine plus nab-paclitaxel as first-line therapy for older adult patients with unresectable pancreatic cancer: A prospective study.
Authors
Kenji Ikezawa
Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan
Kenji Ikezawa , Toshihiro Imai , Ryoji Takada , Takuo Yamai , Nobuyasu Fukutake , Kazuyoshi Ohkawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
jRCTs051190038
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 672)
DOI
10.1200/JCO.2024.42.3_suppl.672
Abstract #
672
Poster Bd #
M1
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Gemcitabine plus nab-paclitaxel versus gemcitabine alone in elderly patients aged 76 years or older with unresectable pancreatic cancer: A propensity score-matched multicenter prospective observational study.
First Author: Satoshi Kobayashi
Poster
2019 Gastrointestinal Cancers Symposium
Results from phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer.
First Author: Yusuke Hashimoto
Poster
2017 Gastrointestinal Cancers Symposium
Clinical outcome of modified FOLFIRINOX versus Gemcitabine plus nab-paclitaxel as first line chemotherapy in metastatic pancreatic cancer.
First Author: Kazuo Watanabe
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
First Author: Yan-Shen Shan